

**Amendments to the Specification:**

Page 1, after the title, insert the following paragraph:

This Application is the National Phase of International Application No. PCT/JP2005/005967 filed March 29, 2005, which designated the U.S. and was not published under PCT Article 21(2) in English, and this application claims, via the aforesaid International Application, the foreign priority benefit of and claims the priority from Japanese Patent Application No. 2004-98542, filed March 30, 2004, Japanese Patent Application No. 2004-107022, filed March 31, 2004, Japanese Patent Application No. 2004-107023, filed March 31, 2004, Japanese Patent Application No. 2004-120771, filed April 15, 2004, and Japanese Patent Application No. 2004-120772, filed April 15, 2004, the complete disclosures of which are incorporated herein by reference.

Please amend the specification at page 3, page 3, lines 23-27 as follows.

Item 5. A pharmaceutical product according to any one of Items 1 to 4, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 365 nm to 430 nm, 20% or lower in the wavelength range from 350 nm to 430 nm, and 20% or lower in the wavelength range from 350 nm to ~~430~~ 450 nm.

Please amend the specification at page 5, lines 13-17 as follows:

Item 16. A method according to any one of Items 12 to 15, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 365 nm to 430 nm, 20% or lower in the wavelength range from 350 nm to 430 nm, and 20% or lower in the wavelength range from 350 nm to ~~430~~ 450 nm.

Please amend the specification at page 6, lines 26-28 as follows:

Item 24. Use of the packaging container according to Item 23, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from ~~360~~ 365 nm to 430 nm.

Please amend the specification at page 7, lines 3-7 as follows:

Item 27. Use of the packaging container according to any one of Items 23 to 26, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 365 nm to 430 nm, 20% or lower in the wavelength range from 350 nm to 430 nm, and 20% or lower in the wavelength range from 350 nm to ~~430~~ 450 nm.

Please amend the specification at page 7, lines 28-30 as follows:

Item 30. Use of the packaging container according to Item 29, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from ~~360~~ 365 nm to 430 nm.

Please amend the specification at page 8, lines 5-9 as follows:

Item 33. Use of the packaging container according to any one of Items 29 to 32, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 365 nm to 430 nm, 20% or lower in the wavelength range from 350 nm to 430 nm, and 20% or lower in the wavelength range from 350 nm to ~~430~~ 450 nm.

Please amend the specification at page 12, lines 10-19 as follows:

In order to impart more excellent photostability to pharmaceutical preparations comprising tranilast and/or its salt, it is more preferable to use a container whose average

light transmittance in the wavelength range from 350 nm to ~~450~~ 430nm (hereafter referred to as "average light transmittance in the 350 nm-~~450~~ 430 nm wavelength range") is 20% or lower, preferably 15% or lower, more preferably 10% or lower, still more preferably 5% or lower, and particularly preferably 3% or lower. The average light transmittance in the 350 nm- ~~450~~ 430 nm wavelength range is determined as in the case of the average light transmittance in the 365 nm-430 nm wavelength range.

Please amend the specification at page 12, lines 30-35 as follows:

In addition, mentionable as one preferable aspect of the packaging container of the invention is, for example, a packaging container in which the average light transmittance in each of the wavelength ranges from 365 nm to 430 nm, 350 nm to ~~450~~ 430 nm, and 350 nm to 450 nm is 20% or lower, preferably 15% or lower, more preferably 10% or lower, and still more preferably 5% or lower.